ErbB2/HER2 Antibody (C-3): sc-377344
- ErbB2/HER2 Antibody (C-3) is a mouse monoclonal IgG2a κ, cited in 5 publications, provided at 200 µg/ml
- raised against amino acids 251-450 mapping within an N-terminal extracellular domain of Neu of human origin
- recommended for detection of Neu of mouse, rat and human origin by WB, IP, IF, IHC(P) and ELISA
- See ErbB2/HER2 (3B5): sc-33684 for ErbB2/HER2 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for ErbB2/HER2 Antibody (C-3) for WB and IHC(P) applications. These reagents are now offered in bundles with ErbB2/HER2 Antibody (C-3) (see ordering information below).
QUICK LINKS
SEE ALSO...
Neu Antibody (C-3) is a mouse monoclonal IgG2a antibody that detects Neu in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Neu, a member of the epidermal growth factor receptor family, plays a critical role in cellular signaling pathways that regulate cell growth, survival, and differentiation. anti-Neu antibody (C-3) forms heterodimers with other EGF receptor family members, such as ErbB-3, leading to heregulin recruitment, which activates phosphoinositide 3-kinase. This activation promotes tumor cell motility, enhances protease secretion, and facilitates invasion, while influencing cell cycle checkpoints, DNA repair mechanisms, and apoptotic responses. Notably, amplification or overexpression of Neu occurs in 20-30% of breast carcinomas, making Neu (C-3) antibody a valuable biomarker for disease prognosis and a promising target for therapeutic interventions. Neu monoclonal antibody (C-3) serves as an indispensable tool for researchers investigating Neu′s role in cancer biology and therapeutic development.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
ErbB2/HER2 Antibody (C-3) References:
- Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. | Yu, D., et al. 1992. Oncogene. 7: 2263-70. PMID: 1359495
- Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth. | Andrechek, ER., et al. 2005. Oncogene. 24: 932-7. PMID: 15580295
- Genome profiling of ERBB2-amplified breast cancers. | Sircoulomb, F., et al. 2010. BMC Cancer. 10: 539. PMID: 20932292
- Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1. | Li, G., et al. 2014. PLoS One. 9: e106349. PMID: 25238247
- Neratinib in ERBB2-Positive Brain Metastases. | Pegram, MD. 2016. JAMA Oncol. 2: 1541-1543. PMID: 27077740
- Stromal SNAI2 Is Required for ERBB2 Breast Cancer Progression. | Blanco-Gómez, A., et al. 2020. Cancer Res. 80: 5216-5230. PMID: 33023950
- Sequential HER2-Targeted Therapy in Salivary Ductal Carcinoma With HER2/neu Overexpression and a Concomitant ERBB2 Mutation. | Almquist, D., et al. 2018. JCO Precis Oncol. 2: 1-5. PMID: 35135125
- Cerulenin suppresses ErbB2-overexpressing breast cancer by targeting ErbB2/PKM2 pathway. | Lv, S., et al. 2022. Med Oncol. 40: 5. PMID: 36308575
- The neu-protein and breast cancer. | De Potter, CR. and Schelfhout, AM. 1995. Virchows Arch. 426: 107-15. PMID: 7757280
- Overexpression of neu-related lipocalin (NRL) in neu-initiated but not ras or chemically initiated rat mammary carcinomas. | Stoesz, SP. and Gould, MN. 1995. Oncogene. 11: 2233-41. PMID: 8570173
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ErbB2/HER2 Antibody (C-3) | sc-377344 | 200 µg/ml | $322.00 | |||
ErbB2/HER2 Antibody (C-3): m-IgG Fc BP-HRP Bundle | sc-538041 | 200 µg Ab; 10 µg BP | $361.00 | |||
ErbB2/HER2 Antibody (C-3): m-IgGκ BP-HRP Bundle | sc-535565 | 200 µg Ab; 40 µg BP | $361.00 |